DP
BMRN icon

Diadema Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Diadema Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.9M Buy
312,846
+164,617
+111% +$9.02M 2.26% 12
2026
Q1 		$8.37M Buy
148,229
+1,868
+1% +$109K 1.42% 24
2025
Q4 		$8.7M Sell
146,361
-66,516
-31% -$3.62M 1.5% 21
2025
Q3 		$11.5M Buy
212,877
+20,000
+10% +$1.14M 2.95% 6
2025
Q2 		$10.6M Buy
192,877
+140,000
+265% +$8.24M 3.23% 9
2025
Q1 		$3.74M Buy
+52,877
New +$3.56M 0.98% 27

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Diadema Partners's BMRN Position: Q2 2026 in Review

Diadema Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 111% in Q2 2026, buying an estimated $9.02M and bringing the position to 312,846 shares worth $17.9M. The position accounts for 2.26% of the portfolio, ranked #12.

Diadema Partners first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Diadema Partners held 312,846 shares of BioMarin Pharmaceuticals worth $17.9M as of Q2 2026.
  • Diadema Partners bought 164,617 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $9.02M.
  • BioMarin Pharmaceuticals made up 2.26% of Diadema Partners's portfolio in Q2 2026, its #12 holding.
  • Diadema Partners first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.